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Hepatitis is a potentially life-threatening viral infection that can 
be caused by the hepatitis A, B, C, D or E viruses.[1] Of these five 
types, hepatitis B virus (HBV) infection is the commonest and poses 
a major global health problem. It can result in chronic infection, 
putting people at an increased risk of death from cirrhosis and liver 
cancer.[1,2] The World Health Organization (WHO) estimates that 
15 - 60% of the apparently healthy population in many African 
countries may be positive for one or more of the HBV serological 
markers.[1,2] Data on both the population-based and facility-based 
HBV burden in sub-Saharan Africa (SSA) are limited, but the rate 
of chronic HBV infection is estimated to be >8% in this region.[1-3] 
Prevention of hepatitis B includes vaccination, screening, monitoring 
asymptomatic positive patients (and treating them with antivirals if 
necessary), and follow-up care for symptomatic patients.[4,5]
Namibia, with a population of 2.3 million, currently has 14 political 
regions, but at the time of the study there were 13 regions, and our 
analysis is based on the latter figure.[5] The regions are further divided 
into regional constituencies, localities and villages. The regional 
health directorates are subdivided into 34 health districts, 34 district 
hospitals, 44 health centres and over 265 clinics.[5] There are four 
main private hospitals with numerous smaller private care facilities 
across the country.[5] The Namibia Institute of Pathology (NIP) is the 
main laboratory, and has a presence in each of the 34 health districts. 
All the pathology test results are captured in the central NIP database 
in Windhoek. The Ministry of Health and Social Services (MoHSS) 
antiretroviral therapy (ART) policy requires that: (i) all pregnant 
women be screened for hepatitis B at their first antenatal care (ANC) 
clinic visit; and (ii) all HIV-positive clients be screened during their 
first ART visit, so that HBV infection can be identified early and 
remedial action taken.[5] Furthermore, doctors would normally 
request a laboratory test for hepatitis B for people presenting with 
jaundice or any suspected liver disease, to rule out HBV infection.
As in many SSA countries, data on the burden of viral hepatitis 
in Namibia are limited.[5,6] Available HBV prevalence data are from 
studies conducted more than two decades ago. These include a 
prevalence study in a general population in Kavango region in 1983,[7] 
studies on the carrier state in children in Ovamboland in 1984[8] 
and on serological markers of HBV in Eastern Caprivi in 1991,[9] 
and a study of the !Kung children in Bushmanland in 1994.[10] HBV 
prevalence in these studies ranges from 11% to 17%. The absence 
of recent and updated HBV data may compromise the country’s 
efforts to initiate an informed and appropriate national viral hepatitis 
strategy in 2016 - 2021 and to achieve the goal of global elimination 
of hepatitis B and C by 2030, as recommended by the WHO.
Objective
To investigate the distribution of HBV infection in Namibia using the 
pre-existing NIP laboratory data for 2013, to provide an update on 
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Background. Namibia regards hepatitis B virus (HBV) infection as a public health problem and introduced hepatitis B vaccinations for 
infants during 2009. However, information on HBV infection in the country remains limited, and effective public health interventions may 
be compromised in the absence of adequate evidence-based data. Available data from the World Health Organization (WHO) estimate that 
15 - 60% of the normal population in many African countries may be positive for one or more of the HBV serological markers.
Objective. To investigate the distribution of HBV infection in Namibia, using available laboratory data for 2013.
Methods. A cross-sectional descriptive study was conducted using pre-existing electronic laboratory data on HBV infection. The data 
were retrieved from the central Namibia Institute of Pathology laboratory in Windhoek during January - December 2013. Tests were done 
on the following three main groups: (i) pregnant women during routine antenatal care (ANC) visits; (ii) patients with HIV/AIDS during 
antiretroviral therapy clinic visits; and (iii) any other individual suspected of having HBV infection.
Results. Of a total of 77 238 hepatitis B surface antigen test results retrieved countrywide, 9 087 (11.8%) were positive. Of the positive results, 
246/9 087 (2.7%) were in children aged 0 - 14 years, with the sexes equally affected. HBV infections increased markedly, particularly among 
females, in the age group 15 - 39 years, reaching a peak in the age group 30 - 34 years. Routine screening of pregnant women for HBV during 
ANC visits was found to be systematically conducted in only two regions, Ohangwena and Khomas.
Conclusions. This study showed high proportions of positive results in pregnant women, patients with HIV/AIDS and individuals suspected 
of having HBV infection. The Ministry of Health and Social Services and stakeholders may wish to consider improving the routine and 
surveillance reporting systems for viral hepatitis and uptake of screening for pregnant women in all regions, and expanding HBV screening 
to other population groups. Population-based or similar studies are therefore required to determine the HBV prevalence and risk factors. 
This will assist Namibia in developing appropriate national viral hepatitis strategies as per WHO recommendations.
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and evidence-based policy guidance for HBV prevention and control 
in the country.
Methods
Design. This was a cross-sectional descriptive health facility-based 
study of all pre-existing test results for hepatitis B that were extracted 
from the main NIP laboratory database in Windhoek during 1 Janu-
ary - 31 December 2013.
Setting. The Windhoek NIP laboratory is the central point where 
the database of all results of specimens taken or tested in all district or 
health facility NIP laboratories countrywide is located and managed.
Study population. The study population included: (i) all pregnant 
women who were tested for HBV during their first ANC visit; (ii) 
all patients with HIV/AIDS who were tested for HBV during their 
routine ART visits; and (iii) any other individual suspected of having 
HBV infection. The three groups were inferred from information on 
laboratory request forms, e.g. those with HAART/CDC/ARV on their 
form were categorised as patients with HIV/AIDS, and those with 
Maternity/ANW/ANCW/ANC on their form were categorised as 
pregnant women or infants, depending on age and sex.
For the purposes of the study, if individual results were not 
explicitly recorded as ANC or HIV/AIDS-related (as described 
above) on the request form, they were grouped as ‘tested on 
clinical suspicion’. The accuracy of the information recorded by the 
requesting clinician could not be verified. In addition, demographic 
and clinical information on the patients was sometimes either 
missing or incomplete.
Serological testing. The NIP laboratory uses the ARCHITECT 
hepatitis B surface antigen (HBsAg) qualitative assay (Abbott 
Laboratories, Sligo, Ireland) which is a chemiluminescent micro-
particle immunoassay for the qualitative detection of HBsAg in 
human serum and plasma.
Statistical analysis. Records were retrieved and cleaned by remov-
ing obvious duplications or inconsistencies. Duplications were identi-
fied through filtering for surname, sex and age. These records were 
then reviewed and deleted if found to be duplicates. Data were ana-
lysed using IBM SPSS Statistics, version 24 (IBM Corporation, USA).
Ethical considerations. Permission to conduct the survey 
was granted by the permanent secretary of the MoHSS (ref. no. 
17/3/3) and the chief executive officer of the NIP laboratories (no 
reference number provided). After the database had been filtered for 
duplications, the data were de-identified to ensure confidentiality.
Results
A total of 77 238 HBsAg test results were retrieved and analysed 
during the study period. A total of 9 087 results (11.8%) were positive, 
and these were analysed by region and by selected population groups.
Kavango region showed the highest number of positive results for 
HBV (n=2 027, 16.3%), followed by Ohangwena (n=535, 11.2%) and 
Omusati (n=820, 16.1%) (Table 1).
The HBV-positive results from Kavango region represented 22.3% 
of the total positive results in the country, and the positive results 
from Ohangwena and Khomas represented 16.9% each. The health 
facilities in eight regions, starting from Otjozondjupa northwards and 
including those bordering Angola and Zambia, showed the highest 
HBsAg positivity rates in the country (Fig. 1). Kavango, Ohangwena 
and Khomas also had the highest number of HBV-positive results in 
the age group 15 - 34 years.
Of the total 9 087 positive HBV test results, 5 391 (59.3%) were 
for females and 3 519 (38.7%) for males (gender was missing for 177 
positive results (1.9%)).
Of the positive results, 246/9 087 (2.7%) were in children aged 0 - 
14 years, with the sexes equally affected. Fig. 2 shows that there was 
a high rate of HBV-positive results in the age group 15 - 39 years 
(72.9%, 6 625 out of the total 9 087 positive results). Females were the 
most affected, with over twice as many positive results than males, 
peaking in the age group 30 - 34 years. From the age of 40 years, 
however, the number of positive HBV test results for males exceeded 
that for females (1 238 positive results for males v. 948 for females).
Tables 2 and 3 show further analysis of the HBV screening results 
for routine ANC clients and for people living with HIV/AIDS, as 
well as those tested on clinical suspicion for hepatitis B or unknown 
reasons on the laboratory request form.
The numbers and proportions of positive HBV results in the HIV-
positive patients tested at ART visits, and in the pregnant women 
who were tested at ANC visits, were 1 819 (20.0%) and 836 (9.2%), 
respectively. The remaining positive HBV results (‘other’), numbering 
6 432 (70.8%) of the total 9 087 positive results, included the results 
Table 1. Hepatitis B virus results by region, Namibia, 2013
Region Total tests, N
Negative,  
n (%)
Positive,  
n (%)
Erongo 5 512 5 053 (91.7) 459 (8.3)
Hardap 1 694 1 540 (90.9) 154 (9.1)
Karas 1 596 1 447 (90.7) 149 (9.3)
Kavango 12 469 10 442 (83.7) 2 027 (16.3)
Khomas 17 106 15 573 (91.0) 1 533 (9.0)
Kunene 1 388 1 220 (87.9) 168 (12.1)
Ohangwena 13 713 12 178 (88.8) 1 535 (11.2)
Omaheke 1 949 1 771 (90.9) 178 (9.1)
Omusati 5 093 4 273 (83.9) 820 (16.1)
Oshana 6 003 5 225 (87.0) 778 (13.0)
Oshikoto 4 149 3 595 (86.6) 554 (13.4)
Otjozondjupa 3 136 2 795 (89.1) 341 (10.9)
Zambezi 3 430 3 039 (88.6) 391 (11.4)
Total 77 238 68 151 (88.2) 9 087 (11.8)
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Fig. 1. Hepatitis B virus infections in Namibia by region, 2013, using pre-
existing laboratory data.
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of tests requested on clinical grounds and 
results with missing information or inaccu-
rate information captured on the laboratory 
request form.
Routine screening for HBV of pregnant 
women during ANC visits was found to 
be systematically conducted only in two 
regions, Ohangwena, with 415 (10.1%) 
positive out of 4 096 test results, and 
Khomas, with 350 (5.6%) positive out of 
6 235 test results (Table  3). Data on HBV 
screening of pregnant women from the 
remaining 11 regions were incomplete or 
missing (Tables  2 and 3).
A total of 836 (7.3%) of 11 390 (positive 
plus negative) HBV results retrieved for preg-
nant women were positive. For patients with 
HIV/AIDS (i.e. co-infected with HBV and 
HIV/AIDS), the figure was 1 819 (13.6%) out 
of 13 456 results retrieved (Table 3).
Omusati region recorded the highest 
posi tivity rate of 17.0% (HIV/HBV co- 
infection). Rates of HBV/HIV co-infection 
were also high in Oshikoto (15.3%), 
Kavango (14.4%), Kunene (14.1%), Oshana 
(13.5%) and Ohang wena (13%). With the 
exception of Karas (6.1%), all the regions 
had HIV/HBV co- infection rates >10%.
The HBV positivity rate for individuals 
tested on clinical grounds or for other reasons 
was 12.3% (6 432 positive out of a total of 52 
392 tests in this category) (Table 3).
Data from the annual returns of the 
MoHSS health information system on hepa-
ti tis B notifications to the MoHSS Health 
Information System (inpatients and out-
patients) showed a total of only 501 cases of 
hepatitis B during January - December 2013 
nationally, compared with 77 238 test results 
retrieved from the NIP laboratory database, 
of which 9 087 were positive, during the 
same reporting period.
Discussion
This study findings show that rates of HBV-
positive results were very high (11.8%) in 
Namibia, particularly in the seven northern 
regions of Kavango, Omusati, Ohangwena, 
Oshikoto, Oshana, Kunene and Zambezi 
(formerly Caprivi). These findings are 
similar to those in a prevalence study 
conducted in 1983 in Kavango by Joubert et 
al.,[7] which showed an HBsAg prevalence 
of 13.6%. The current study showed the rate 
of positive results to be highest for Kavango 
(16.3%).
A high proportion of positive results 
among 0 - 14-year-olds nationally (246 
(2.7%) of the total of 9 087 positive results) 
can be attributed to historical trends in the 
northern regions that include both vertical 
transmission of HBV and later horizontal 
transmission during early childhood. This is 
in accordance with a 1984 study of hepatitis 
B in children in Ovamboland, Namibia, 
by Botha et al.,[8] which showed a 13% rate 
of HBsAg positivity among children aged 
≥6 months.[8] A study of HBsAg prevalence 
among the !Kung (San) children in 1994 
showed a similar trend, with a figure of 
7.8%.[10] We found that positive results in the 
age group 10 - 14 years occurred mainly in 
the northern regions, i.e. Kavango (19.8%), 
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Fig. 2. Hepatitis B virus results by age and sex, using pre-existing laboratory data, Namibia, 2013 
(N=9  087).
Table 2. Hepatitis B virus-positive results as proportions of total positive results by region, Namibia, 2013
Region
Total positive  
results, N
Pregnant women, n  
(% of total positive 
results)
HIV-positive patients 
(HBV/HIV co-infection), 
n (% of total positive 
results) 
Other (tested on clinical 
grounds or for unknown 
reasons), n (% of total 
positive results)
Erongo 459 17 (3.7)* 43 (9.4)* 399 (87.0)*
Hardap 154 † † 154 (100)*
Karas 149 † 26 (17.5)* 123 (82.6)*
Kavango 2 027 1* 428 (21.1) 1 598 (78.8)*
Khomas 1 533 350 (22.8) 301 (19.6) 882 (57.5)
Kunene 168 † 98 (58.3) 70 (41.7)*
Ohangwena 1 535 415 (27.0) 257 (16.7) 863 (56.0)
Omaheke 178 † 60 (33.7)* 118 (66.3)*
Omusati 820 48 (5.9)* 425 (51.8) 347 (42.3)
Oshana 778 4 (0.5)* 37 (4.8)* 737 (94.7)*
Oshikoto 554 0 (0.0)* 30 (5.4)* 524 (94.6)*
Otjozondjupa 341 † 114 (33.4) 227 (66.6)*
Zambezi 391 1 (0.3)* † 390 (99.7)*
Namibia 9 087 836 (9.2)* 1 819 (20.0)* 6 432 (70.8)*
HBV = hepatitis B virus.
*Includes results with missing information, or inaccurate information captured on the laboratory request form that could have led to overestimation of positive results.†No HBV screening done/no test results found.
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Omusati (19.8%) and Ohangwena (14.9%), together with Khomas 
(13.2%), where Namibia’s capital city is situated. HBsAg rates are 
similar in many other sub-Saharan African countries.[11-13]
HBsAg screening of pregnant women was not done systematically 
in 11 out of 13 regions, and data capturing on the laboratory request 
forms may have been inaccurate, resulting in over-estimation of 
positive results in the category of tests done on clinical grounds. HBV 
screening of pregnant women needs to be strengthened to improve 
early detection and consequent prevention of vertical transmission 
from the infected mother to the newborn.
The HBV positivity and HBV/HIV co-infection rates of 11.8% 
and 13.6% in this study were based on only a small proportion of 
the Namibian population – mainly pregnant women, people with 
HIV/AIDS, and individuals with signs and symptoms suggestive of 
viral hepatitis. The vast majority, who are not pregnant or whose 
HIV status is unknown, will remain undiagnosed and in many cases 
continue to constitute a reservoir of infection and a threat to their 
household, social and sexual contacts. They are likely to be screened 
only when they present with clinical features of liver disease and 
even evidence of complications. Namibia must be commended 
for maintaining high HBV immunisation coverage of infants aged 
<1 year (83%), although there is a need to improve coverage of 
healthcare workers.[11,13]
Recommendations
The study findings have several implications for Namibia’s public health 
programmes. While the data are clearly limited, there is evidence of a 
significant burden of HBV in the country. Further prospective studies 
should be planned and carried out in order to address key issues 
facing the Namibian MoHSS. These include expanding immunisation 
to other age groups, and treatment and monitoring of HBV-positive 
individuals who are not pregnant or are of unknown HIV status. 
Significant work is needed to improve the information captured at and 
recorded from the clinical sites. Better data collection and storage will 
allow for a more informed and programmatic approach to the public 
health control of HBV in Namibia.
Study limitations
These findings are based on health facility data only, and some 
duplicate test results may have been included in the analysis. 
Furthermore, it was not possible to identify risk factors that could 
be associated with sociocultural and economic variables in the 
population-derived samples. While the findings could be useful 
in estimating health facility-based HBV prevalence in specific 
selected groups or regions, they may not be generalisable to or a 
true representation of the general population. Data capturing for 
morbidity and mortality due to HBV infections, including liver 
cancer, in Namibia are generally insufficient to provide evidence-
based policy/strategy guidance.
Conclusions
This study showed high proportions of positive results among 
pregnant women, people with HIV/AIDS, and individuals suspected 
of having HBV infection on clinical grounds. However, the general 
population, who are not pregnant or whose HIV status is unknown, 
are unlikely to have access to HBV screening.
The MoHSS and stakeholders may wish to consider improving the 
uptake of screening for pregnant women, and even expanding HBV 
screening to other population groups. Furthermore, the identification 
and management of HBV-positive women and their newborns may 
need to be improved to prevent or reduce vertical transmission.
Viral hepatitis seems to be under-reported by both the routine 
and surveillance reporting systems in Namibia. This compromises 
evidence-based national strategy development for attaining the 
WHO goal of global elimination of hepatitis B and C by the year 
2030. Population-based or similar studies are therefore required 
to determine the prevalence of and risk factors for HBV. This will 
assist the country in developing appropriate national viral hepatitis 
strategies as per the WHO recommendations.
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Table 3. Hepatitis B virus-positive results v. positive plus negative results, Namibia, 2013 
Region
Pregnant women, n 
positive results/N positive 
+ negative results (%)
HIV-positive patients, n 
positive results/N positive 
+ negative results (%)
Other (tested on clinical 
grounds or for unknown 
reasons), n positive results/ 
N positive + negative 
results (%)
Total, n positive results/ 
N positive + negative 
results (%)
Erongo 17/265 (6.4)* 43/343 (12.5)* 399/4 904 (8.1)* 459/5 512 (8.3)* 
Hardap † † 154/1 694 (9.0)* 154/1 694 (9.1)* 
Karas † 26/427 (6.1)* 123/1 169 (10.5)* 149/1 596 (9.3)*
Kavango 1/13 (7.7)* 428/2 971 (14.4) 1 598/9 485 (16.8)* 2 027/12 469 (16.3)*
Khomas 350/6 235 (5.6) 301/2 539 (11.9) 882/8 332 (10.6) 1 533/17 106 (9.0) 
Kunene † 98/694 (14.1) 70/694 (10.1)* 168/1 388 (12.1)* 
Ohangwena 415/4 096 (10.1) 257/1 974 (13.0) 863/7 643 (11.3) 1 535/13 713 (11.2) 
Omaheke † 60/480 (12.5)* 118/1 469 (8.0)* 178/1 949 (9.1)*
Omusati 48/705 (6.8)* 425/2 501 (17.0) 347/1 887 (18.4) 820/5 093 (16.1) 
Oshana 4/47 (8.5)* 37/275 (13.5)* 737/5 681 (13.0)* 778/6 003 (13.0)*
Oshikoto 0/15 (0.0)* 30/196 (15.3)* 524/3 938 (13.3)* 554/4 149 (13.3)* 
Otjozondjupa † 114/1 056 (10.8) 227/2 080 (10.9)* 341/3 136 (10.9)*
Zambezi 1/14 (7.1)* † 390/3 416 (11.4)* 391/3 430 (11.4)*
Namibia 836/11 390 (7.3)* 1 819/13 456 (13.6)* 6 432/52 392 (12.3)* 9 087/77 238 (11.8)*
*Includes results with missing information, or inaccurate information captured on the laboratory request form that could have led to overestimation of positive results.†No hepatitis B virus screening done/no test results found.
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